Case Report
Copyright ©The Author(s) 2015.
World J Gastroenterol. Aug 28, 2015; 21(32): 9666-9670
Published online Aug 28, 2015. doi: 10.3748/wjg.v21.i32.9666
Figure 1
Figure 1 Tumor evolution throughout the therapeutic sequence. A: Contrast-enhanced computed tomography (CT) scan at presentation showing, in portal phase, a 167 mm tumor in segment VIII with features of hepatocellular carcinoma; B: Yttrium-90 (90Y) positron emission tomography (PET)-CT performed 12 hours after transarterial radioembolization (TARE). Images are displayed in orthogonal views, centered on the liver tumor. Upper row: CT scan without contrast. Middle row: 90Y emission PET images showing high and selective accumulation of 90Y microspheres in the tumor site. Lower row: fused 90Y PET-CT images; C: Contrast-enhanced CT scan 17 wk after TARE and 6 wk after portal vein embolization showing, in portal phase, a 50% tumor volume reduction and hypertrophy of the future remnant left liver.